Analyst Price Target is C$0.00
This price target is based on 0 analysts offering 12 month price targets for Neovasc in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Neovasc. This rating has held steady since July 2023, when it changed from a Buy consensus rating.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Read More